SLC5A2 and fatty liver disease: Future large-scale RCTs with individual-level data are essential to better understand the role of baseline metabolic status, genetic factors, and concurrent lifestyle modifications in determining the efficacy of SGLT2 inhibitors in reducing hepatic steatosis.